388 related articles for article (PubMed ID: 11347115)
1. [KLAS [Kanazawa Lipid Assessment Survey]].
Mabuchi H; Inazu A; Higashikata T; Nohara A; Koizumi J
Nihon Rinsho; 2001 Mar; 59 Suppl 3():469-76. PubMed ID: 11347115
[No Abstract] [Full Text] [Related]
2. [Helsinki Heart Study].
Sekiya M; Ishibashi S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
[No Abstract] [Full Text] [Related]
3. [J-LIT [Japan Lipid Intervention Trial]].
Itakura H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():462-8. PubMed ID: 11347114
[No Abstract] [Full Text] [Related]
4. [Nicotinic acid and the derivative].
Ogaki S; Matsushima T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
[No Abstract] [Full Text] [Related]
5. [Fenofibrate].
Yamashita T; Nakamura H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():618-24. PubMed ID: 11347142
[No Abstract] [Full Text] [Related]
6. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Dobordzhginidze LM
Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
[No Abstract] [Full Text] [Related]
7. [Statins (HMG-CoA reductase inhibitors)].
Gotoda T
Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
[TBL] [Abstract][Full Text] [Related]
8. [Gemfibrozil: new aspects in clinical use].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():625-30. PubMed ID: 11347143
[No Abstract] [Full Text] [Related]
9. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
[No Abstract] [Full Text] [Related]
10. Implications of 4S evidence on baseline lipid levels.
Durrington PN
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
[No Abstract] [Full Text] [Related]
11. Implications of 4S evidence on baseline lipid levels.
Ravnskov U
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
[No Abstract] [Full Text] [Related]
12. [Multipurpose psyllium monotherapy in patients with diverticular disease].
Komissarenko IA; Levchenko SV; Sil'vestrova SIu; Kosacheva TA; Noskova KK
Eksp Klin Gastroenterol; 2012; (3):62-7. PubMed ID: 22830226
[TBL] [Abstract][Full Text] [Related]
13. [Overviews of fibrate].
Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
[No Abstract] [Full Text] [Related]
14. How should HIV patients lower lipid levels?
Brown BR
HIV Clin; 2000; 12(3):1, 6-8. PubMed ID: 11810836
[No Abstract] [Full Text] [Related]
15. Who decides when to start preventive treatment? A questionnaire survey to compare the views of different population subgroups.
Lewis DK; Barton S
J Epidemiol Community Health; 2003 Apr; 57(4):241-2. PubMed ID: 12646536
[No Abstract] [Full Text] [Related]
16. [Hyperlipidemia complicated with hypertension].
Takagi S; Shimamoto K
Nihon Rinsho; 2001 Mar; 59 Suppl 3():738-42. PubMed ID: 11347164
[No Abstract] [Full Text] [Related]
17. A symposium: lipid management summit on improving practice outcome. Introduction.
Ballantyne CM
Am J Cardiol; 2000 Feb; 85(3A):1A-2A. PubMed ID: 10695700
[No Abstract] [Full Text] [Related]
18. Primary prevention of coronary heart disease: where do we go from here?
Gotto AM
Arch Intern Med; 2001 Apr; 161(7):922-4. PubMed ID: 11295953
[No Abstract] [Full Text] [Related]
19. Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing.
Gerrald KR; Dixon DL; Barnette DJ; Williams VG
J Clin Lipidol; 2010; 4(2):120-5. PubMed ID: 21122639
[TBL] [Abstract][Full Text] [Related]
20. Assessment and management of vascular disease risk in patients with chronic kidney disease.
Brown WV; Bakris G; Lerma E; Chertow G
J Clin Lipidol; 2011; 5(4):251-60. PubMed ID: 21784369
[No Abstract] [Full Text] [Related]
[Next] [New Search]
